SIRT1 Activation by Small Molecules

SIRT1 is a protein deacetylase that has emerged as a therapeutic target for the development of activators to treat diseases of aging. SIRT1-activating compounds (STACs) have been developed that produce biological effects consistent with direct SIRT1 activation. At the molecular level, the mechanism by which STACs activate SIRT1 remains elusive. In the studies reported herein, the mechanism of SIRT1 activation is examined using representative compounds chosen from a collection of STACs. These studies reveal that activation of SIRT1 by STACs is strongly dependent on structural features of the peptide substrate. Significantly, and in contrast to studies reporting that peptides must bear a fluorophore for their deacetylation to be accelerated, we find that some STACs can accelerate the SIRT1-catalyzed deacetylation of specific unlabeled peptides composed only of natural amino acids. These results, together with others of this study, are at odds with a recent claim that complex formation between STACs and fluorophore-labeled peptides plays a role in the activation of SIRT1 (Pacholec, M., Chrunyk, B., Cunningham, D., Flynn, D., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., Qiu, X., Stockman, B., Thanabal, V., Varghese, A., Ward, J., Withka, J., and Ahn, K. (2010) J. Biol. Chem. 285, 8340–8351). Rather, the data suggest that STACs interact directly with SIRT1 and activate SIRT1-catalyzed deacetylation through an allosteric mechanism.

[1]  R. Schnellmann,et al.  SRT1720 Induces Mitochondrial Biogenesis and Rescues Mitochondrial Function after Oxidant Injury in Renal Proximal Tubule Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.

[2]  A. Railkar,et al.  Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675). , 2010, Journal of medicinal chemistry.

[3]  J. Baur Resveratrol, sirtuins, and the promise of a DR mimetic , 2010, Mechanisms of Ageing and Development.

[4]  R. Harris,et al.  Sirt1 activation protects the mouse renal medulla from oxidative injury. , 2010, The Journal of clinical investigation.

[5]  L. Guarente Sirtuins in aging and disease. , 2007, Cold Spring Harbor symposia on quantitative biology.

[6]  J. Olefsky,et al.  SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. , 2010, American journal of physiology. Endocrinology and metabolism.

[7]  J. Zorn,et al.  Turning enzymes ON with small molecules. , 2010, Nature chemical biology.

[8]  M. Laakso,et al.  SIRT1 mRNA Expression May Be Associated With Energy Expenditure and Insulin Sensitivity , 2010, Diabetes.

[9]  D. Sinclair,et al.  Mammalian sirtuins: biological insights and disease relevance. , 2010, Annual review of pathology.

[10]  Venkataraman Thanabal,et al.  SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1♦ , 2010, The Journal of Biological Chemistry.

[11]  Shu-Chen Lu,et al.  Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity , 2009, Chemical biology & drug design.

[12]  Brian C. Smith,et al.  A continuous microplate assay for sirtuins and nicotinamide-producing enzymes. , 2009, Analytical biochemistry.

[13]  K. Tsuneyama,et al.  Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. , 2009, American journal of physiology. Endocrinology and metabolism.

[14]  M. McBurney,et al.  SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol , 2009, Oncogene.

[15]  D. Selkoe,et al.  Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening , 2009, PloS one.

[16]  Amy V. Lynch,et al.  Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. , 2009, Bioorganic & medicinal chemistry letters.

[17]  David J. Gagne,et al.  Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo , 2009, BMC Syst. Biol..

[18]  David P. Carney,et al.  Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3 , 2009, Protein science : a publication of the Protein Society.

[19]  Amy V. Lynch,et al.  Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. , 2009, Journal of medicinal chemistry.

[20]  J. Olefsky,et al.  SIRT1 Exerts Anti-Inflammatory Effects and Improves Insulin Sensitivity in Adipocytes , 2008, Molecular and Cellular Biology.

[21]  J. Auwerx,et al.  Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. , 2008, Cell metabolism.

[22]  J. Yates,et al.  A Fasting Inducible Switch Modulates Gluconeogenesis Via Activator-Coactivator Exchange , 2008, Nature.

[23]  Amy V. Lynch,et al.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.

[24]  P. Puigserver,et al.  Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α , 2006, Cell.

[25]  J. Boeke,et al.  The biochemistry of sirtuins. , 2006, Annual review of biochemistry.

[26]  S. Fields,et al.  Substrate-specific Activation of Sirtuins by Resveratrol* , 2005, Journal of Biological Chemistry.

[27]  Brian C. Smith,et al.  Mechanism of Human SIRT1 Activation by Resveratrol* , 2005, Journal of Biological Chemistry.

[28]  L. Hersh,et al.  ATP Effects on Insulin-degrading Enzyme Are Mediated Primarily through Its Triphosphate Moiety* , 2004, Journal of Biological Chemistry.

[29]  K. Glaser,et al.  Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. , 2004, Analytical biochemistry.

[30]  J. Denu,et al.  Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases. , 2004, Biochemistry.

[31]  Namjin Chung,et al.  Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ , 2004, Nature.

[32]  Phuong Chung,et al.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.

[33]  V. Schramm,et al.  Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. , 2003, Biochemistry.

[34]  J. Boeke,et al.  Chemistry of gene silencing: the mechanism of NAD+-dependent deacetylation reactions. , 2001, Biochemistry.

[35]  P. Reichard,et al.  Allosteric control of the substrate specificity of the anaerobic ribonucleotide reductase from Escherichia coli. , 1994, The Journal of biological chemistry.

[36]  R. Stein,et al.  Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. , 1986, The Journal of biological chemistry.

[37]  J. Changeux,et al.  Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.

[38]  A. G. Cooper,et al.  Allosteric activation of the hydrolysis of specific substrates by chymotrypsin. , 1976, European journal of biochemistry.

[39]  F. Wedler Enzyme kinetics: Behavior and analysis of rapid equilibrium and steady‐state enzyme systems. Author: Irwin H. Segal (University of California, Davis). Published by Wiley‐Interscience, New York, 1975. Price: $24.50. No. of pages: 957 , 1976 .